Ascendis Pharma (ASND) Announces Proposed $500M ADS Offering

Ascendis Pharma A/S (NASDAQ: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that it has commenced an underwritten public offering of $500,000,000 of American Depositary Shares (“ADSs”), each of which represents one ordinary share of Ascendis. All of the ADSs are being offered by Ascendis. In addition, Ascendis expects to grant the underwriters a 30-day option to purchase up to an additional $75,000,000 of ADSs at the public offering price, less the underwriting commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Evercore Group L.L.C. and SVB Leerink are acting as joint book-running managers for the offering.

You May Also Be Interested In

• Winnebago Industries refinances credit facility, extends maturity to 2031
• Denarius Metals acquires 15% stake in Copper Giant, Trafigura invests
• enVVeno Medical (NVNO) files $100M mixed shelf